Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3

Gut

Volumn 60, Issue 6, 2011, Pages 879-

  Patel, Harshna ^a   Heathcote, E Jenny ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALISPORIVIR; ASPARTATE AMINOTRANSFERASE; CYCLOPHILIN B; PEGINTERFERON ALPHA2A; RIBAVIRIN; RNA POLYMERASE; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LETTER; LIVER BIOPSY; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; CYCLOSPORINE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; VIRUS REPLICATION;

EID: 79955815806     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.217323     Document Type: Letter

References (7)

1. Himmelsbach K, Sauter D, Baumert TF, et al. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut 2009;58:1644-53.
2. Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006;43:761-70.
3. Inoue K, Umehara T, Ruegg UT, et al. Evaluation of a cyclophilin inhibitor in hepatitis C virus infected chimeric mice in vivo. Hepatology 2007;45:921-8. (Pubitemid 46631561)
4. Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008;47:817-26. (Pubitemid 351449673)
5. Goto K, Watashi K, Murata T, et al. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem Biophys Res Commun 2006;343:879-84.
6. Watashi K, Ishii N, Hijikata M, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005;19:111-22. (Pubitemid 40884662)
7. Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG-IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology 2009;49:1460-8.